Gilead Announces Partial Clinical Hold for Magrolimab Studies in AML
FOSTER CITY, Calif.--(BUSINESS WIRE) August 21, 2023 -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the initiation of new patients in U.S. studies... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 21, 2023 Category: Pharmaceuticals Source Type: clinical trials
First Patient Dosed in Phase 3 Trial of Ivonescimab versus Tislelizumab for First-line Treatment of Squamous NSCLC
HONG KONG, Aug. 18, 2023. Akeso Inc. ( " Akeso " , 9926. HK) announced today that the first patient has been dosed in a head-to-head phase III trial of ivonescimab, a potential first-in-class investigational PD-1/VEGF bi-specific antibody discovered by... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 18, 2023 Category: Pharmaceuticals Source Type: clinical trials
Successful Completion of Phase 1B Clinical Trial for Treatment of Antipsychotic-Induced Weight Gain
FALLS CHURCH, Va., Aug. 17, 2023. Response Pharmaceuticals, Inc. today announced the successful completion of its Phase 1B clinical trial for the company ' s lead drug candidate, RDX-002, a first-in-class inhibitor of intestinal microsomal... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 17, 2023 Category: Pharmaceuticals Source Type: clinical trials
Updated Data from TRIDENT-1 Trial Show Durable Efficacy Benefits with Repotrectinib for Patients with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced updated results from the registrational TRIDENT-1 study, demonstrating that repotrectinib, a next-generation ROS1/TRK tyrosine kinase inhibitor (TKI), continued to... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 16, 2023 Category: Pharmaceuticals Source Type: clinical trials
Sandoz announces positive results from Mylight Phase lll study for biosimilar aflibercept
Basel, August 16, 2023— Sandoz, a global leader in off-patent medicines, today releases positive results from the MYLIGHT Phase III confirmatory efficacy and safety study for its biosimilar aflibercept, for patients living with wet macular... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 16, 2023 Category: Pharmaceuticals Source Type: clinical trials
NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)
Condition: Duchenne Muscular Dystrophy Intervention: Drug: NS-089/NCNP-02 Sponsor: NS Pharma, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 16, 2023 Category: Research Source Type: clinical trials
